William Blair analyst Jon Andersen has maintained their bullish stance on PBH stock, giving a Buy rating on October 21.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jon Andersen has given his Buy rating due to a combination of factors that highlight the strong performance and potential of Prestige Consumer Healthcare. The company’s sales exceeded expectations by 7%, and earnings per share were 10% higher than anticipated, both surpassing consensus estimates. Furthermore, the fiscal 2026 guidance was reaffirmed for sales, and the midpoint of the EPS range was increased, indicating a positive outlook.
Additionally, the improvement in eyecare supply and the steady performance of the rest of the business reinforce the belief in Prestige’s diversified portfolio and its asset-light, cash-generative business model. These elements are seen as supportive of solid long-term shareholder returns. With the stock trading at 12 times the 2026 EPS estimate, Andersen maintains a positive view on the company’s valuation and future prospects.
In another report released on October 21, Oppenheimer also maintained a Buy rating on the stock with a $72.00 price target.